The efficacy of flaxseed oil on non-alcoholic fatty liver disease: a randomised controlled trial

• Published in: Journal of herbal medicine 2024-12, Vol.48, p.100967, Article 100967
• Main Authors: Namdar, Ali Beheshti, Omidvar, Delaram, Amerizadeh, Forouzan, Kabiri, Mona, Namdar, Hediyeh Beheshti, Ravanshad, Sahar
• Format: Article
• Language: English
• Subjects: Fatty liver; Flaxseed oil; Liver disease; Non-alcoholic fatty liver disease (NAFLD); Polyunsaturated fatty acids
• ISSN: 2210-8033
• DOI: 10.1016/j.hermed.2024.100967

Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver disorder and a leading cause of elevated liver enzymes. Previous research indicates that a diet rich in polyunsaturated fatty acids (PUFAs) can alleviate liver insulin resistance. This study investigates the therapeutic effects of flaxseed oil, a primary PUFA source, on NAFLD treatment. In a randomized clinical trial comprising 60 NAFLD patients diagnosed with NAFLD of grades 1, 2, and 3, participants were assigned to either a flaxseed oil capsule or a placebo group, for a total duration of 2 months. Before the intervention, both groups showed no significant differences in examined parameters. However, after the intervention, the flaxseed oil group exhibited significant improvements in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), fasting blood sugar (FBS), and total bilirubin, compared to the placebo group. Specifically, reductions were observed in AST (P = 0.010), ALT (P = 0.047), ALP (P < 0.001), FBS (P = 0.016), and total bilirubin (P = 0.004). These findings suggest that flaxseed oil may hold promise as a therapeutic intervention for NAFLD, highlighting its potential in managing liver disease and metabolic parameters.